|
02.03.2015 09:15:31
|
Medigene AG: Medigene to participate in three upcoming international conferences
Medigene AG / Medigene AG: Medigene to participate in three upcoming international conferences . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 02 March, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming scientific and business development conferences:
-
BIO-Europe Spring 2015 - 9th Annual International Partnering Conference
Date: 09 - 11 March 2015
Location: Paris, France
-
9. Forum Life Science
Date: 11 - 12 March 2015
Location: Munich, Germany
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will conduct a presentation on 12 March titled "The power of T cells in terms of cancer therapy"
-
26th Annual Cancer Progress Conference
Date: 17 - 18 March 2015
Location: New York, USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will be panelist at a discussion on 17 March focussing the topic "Immunotherapy II: Engineered Cell Therapy"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press release distribution list, please visit: http://www.medigene.de/unsubscribe
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Medigenemehr Nachrichten
Analysen zu Medigenemehr Analysen
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.